Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. QGEN
10. SPY

Go back to Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

Exagen Inc. (XGN) Misses Q2 EPS by 21c; Lowers Outlook

August 4, 2022 4:50 PM EDT

Exagen Inc. (NASDAQ: XGN) reported Q2 EPS of ($0.78), $0.21 worse than the analyst estimate of ($0.57). Revenue for the quarter came in at $9 million versus the consensus estimate of $12.03 million.

GUIDANCE:

Exagen Inc. sees Q3 2022 revenue of $35-40 million, versus the consensus of... More